Bladder cancer patients may get new hope from virus treatment
NCT ID NCT07356791
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a virus-based drug given directly into the bladder for people with high-risk non-muscle invasive bladder cancer. The virus is designed to attack cancer cells and trigger the immune system. About 18 participants will receive increasing doses to find the safest and most effective level, with the goal of clearing tumors and preventing their return.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
recombinant human adenovirus type 5 injection
What this could lead to
If it works, this could offer a new treatment option for high-risk bladder cancer patients who have limited alternatives, potentially clearing tumors and delaying recurrence.
What could go wrong
This is a small, early-phase trial with only 18 participants, so results may not apply to everyone. The virus-based therapy can cause side effects like bladder irritation, infection, or bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.